<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004611</url>
  </required_header>
  <id_info>
    <org_study_id>17410</org_study_id>
    <secondary_id>I6T-MC-AMBU</secondary_id>
    <nct_id>NCT04004611</nct_id>
  </id_info>
  <brief_title>A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)</brief_title>
  <acronym>SHINE 1</acronym>
  <official_title>Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate how the body processes and removes mirikizumab. The study
      will also evaluate safety and disease response in pediatric participants with UC taking
      mirikizumab. The study will last about 52 weeks and may include up to 17 visits.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">July 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 21, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Clearance of Mirikizumab</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>Clearance of Mirikizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical Remission based on the modified Mayo Score (MMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Response</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical Response based on the MMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Entered the Study on Corticosteroids and who are in MMS Clinical Remission without the use of Corticosteroids</measure>
    <time_frame>Week 52</time_frame>
    <description>Corticosteroid-free Clinical Remission based on the MMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Remission Based on the Pediatric Ulcerative Colitis Activity Index (PUCAI)</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical Remission based on the PUCAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Response Based on the PUCAI</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical Response based on the PUCAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Endoscopic Remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Endoscopic Remission based on the MMS Endoscopic Subscore (ES)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Symptomatic Remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Symptomatic Remission based on MMS Stool Frequency (SF) and Rectal Bleeding (RB) Subscores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height Velocity (in Centimeters/Year)</measure>
    <time_frame>Week 26, Week 52</time_frame>
    <description>Height Velocity (in Centimeters/Year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Week 52</time_frame>
    <description>Change from Baseline in Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Mucosal Healing</measure>
    <time_frame>Week 12</time_frame>
    <description>Mucosal healing based on a histologic disease activity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 7-day average of Abdominal Pain Numeric Rating Scale (NRS) score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in 7-day average of Abdominal Pain NRS score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Mirikizumab Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered intravenously (IV) and Subcutaneously (SC). Participants &gt;40 kilograms (kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered IV and SC. Participants ≤40 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered IV and SC. Participants ≤40 kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab</intervention_name>
    <description>Administered IV and SC</description>
    <arm_group_label>Mirikizumab Dose 1</arm_group_label>
    <arm_group_label>Mirikizumab Dose 2</arm_group_label>
    <arm_group_label>Mirikizumab Dose 3</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants weighing &gt;10 kg

          -  Participants must have a diagnosis of ulcerative colitis for at least 3 months before
             the planned start date for the study medications

          -  Have moderately to severely active UC as defined by a Modified Mayo Score (MMS) within
             14 days before the first dose of study treatment

          -  Have evidence of UC extending proximal to the rectum

          -  Participants have demonstrated an inadequate response to, a loss of response to, or an
             intolerance to corticosteroids, immunomodulators, Janus kinase inhibitor
             (JAK-inhibitor) or to biologic therapies for UC

        Exclusion Criteria:

          -  Participants with a current diagnosis of Crohn's disease, inflammatory bowel
             disease-unclassified (indeterminate colitis), ulcerative proctitis, or primary
             sclerosing cholangitis

          -  Participants must not have had surgery to remove part of their colon

          -  Participants with current evidence of toxic megacolon

          -  Have received any of the following for treatment of UC: cyclosporine or thalidomide
             within 30 days of screening; corticosteroid enemas, corticosteroid suppositories, or
             topical treatment with 5-aminosalicyclic acid within 1 week of screening

          -  Inadequate response to Interleukin 12 p40 subunit antibody (anti-IL12p40) (e.g.
             ustekinumab) or had prior exposure to anti-IL-23p19 antibodies (e.g. risankizumab,
             brazikumab, guselkumab or tildrakizumab)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>714-509-8810</phone>
    </contact>
    <investigator>
      <last_name>Mitchell Katz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-476-0820</phone>
    </contact>
    <investigator>
      <last_name>Melvin B Heyman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>720-777-2734</phone>
    </contact>
    <investigator>
      <last_name>Edward Hoffenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>860-545-9560</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Hyams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>404-727-4542</phone>
    </contact>
    <investigator>
      <last_name>Subra Kugathasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>773-704-4579</phone>
    </contact>
    <investigator>
      <last_name>Ranjana Gokhale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>1317944-3774</phone>
    </contact>
    <investigator>
      <last_name>Steven Steiner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>617-355-2962</phone>
    </contact>
    <investigator>
      <last_name>Athos Bousvaros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MGH for Children - Waltham</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>617-726-4042</phone>
    </contact>
    <investigator>
      <last_name>Jess Kaplan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>314-454-6173</phone>
    </contact>
    <investigator>
      <last_name>Charles Samson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goryeb Children's Hospital / Atlantic Health System</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>973-971-5676</phone>
    </contact>
    <investigator>
      <last_name>Joel Rosh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn Sch of Med at Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>513-636-4200</phone>
    </contact>
    <investigator>
      <last_name>Phillip Minar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Abbigail Wexner Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>614-722-2593</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Dotson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>267-426-7791</phone>
    </contact>
    <investigator>
      <last_name>Robert Baldassano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>412-692-5180</phone>
    </contact>
    <investigator>
      <last_name>Sapana Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>682-885-1990</phone>
    </contact>
    <investigator>
      <last_name>Clifton Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>832-822-3602</phone>
    </contact>
    <investigator>
      <last_name>Lina Boujaoude Karam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatrics Specialists of Virginia</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>703-876-2788</phone>
    </contact>
    <investigator>
      <last_name>Ian Leibowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>757-668-7240</phone>
    </contact>
    <investigator>
      <last_name>Marc Tsou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital Research Foundation</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>206-987-2521</phone>
    </contact>
    <investigator>
      <last_name>Namita Singh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>17802485420</phone>
    </contact>
    <investigator>
      <last_name>Matthew Carroll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>19024708225</phone>
    </contact>
    <investigator>
      <last_name>Anthony Otley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>4168137734</phone>
    </contact>
    <investigator>
      <last_name>Anne Griffiths</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>972502063333</phone>
    </contact>
    <investigator>
      <last_name>Ron Shaoul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition; Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>97226666482</phone>
    </contact>
    <investigator>
      <last_name>Dan Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Medical Center</name>
      <address>
        <city>Petah Tiqva</city>
        <zip>4920235</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>97239253674</phone>
    </contact>
    <investigator>
      <last_name>Amit Assa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830 0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81942353311</phone>
    </contact>
    <investigator>
      <last_name>Tatsuki Mizuochi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saitama Children's Medical Center</name>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama</state>
        <zip>330 8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>81 48-601-2200</phone>
    </contact>
    <investigator>
      <last_name>Itaru Iwama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81338133111</phone>
    </contact>
    <investigator>
      <last_name>Kudo Takahiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical And Dental University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Masakazu Nagahori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center For Child Health And Development</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>81334160181</phone>
    </contact>
    <investigator>
      <last_name>Katsuhiro Arai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Medical Center Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82534205704</phone>
    </contact>
    <investigator>
      <last_name>Ben Kang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8227433455</phone>
    </contact>
    <investigator>
      <last_name>Jin Soo Moon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/ulcerative-colitis/AMBU#?postal=</url>
    <description>A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)</description>
  </link>
  <verification_date>July 1, 2020</verification_date>
  <study_first_submitted>June 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interleukin-23 (IL-23) antibody</keyword>
  <keyword>IL-23p19</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

